About Biosensors International
With a focus on improving patient outcomes today, while driving the development of tomorrow’s next-generation medical technology, Biosensors has become over the last two-decade a leader in the global coronary stent market. Beyond a strong foothold in cardiovascular devices and critical care products, the company has more recently entered new therapeutic areas as Endovascular and cardiac imaging with enhanced devices and systems.
idsMED and Biosensors International will leverage our joint capabilities in delivering world-class breakthrough products, as well as maximizing the increased market coverage and geographical footprint of the Biosensors.
Founded in 1990, Biosensors International Group, Ltd. are a privately held company. Biosensors International Group, Ltd. develops, manufactures and markets innovative medical devices, aiming to improve patients’ lives through pioneering medical technology that pushes forward the boundaries of innovation.
The Group currently operates through three business units ("BU"): the Cardiovascular BU, composed primarily of the BioMatrix™ family of drug-eluting stents and stent technologies such as BA9; the Cardiac Diagnostic BU, including Spectrum Dynamics products that offer advanced medical imaging and clinical solutions to help interventional cardiologists determine the most appropriate treatment for patients; and the Critical Care Products BU.
The Group has operations worldwide and is headquartered in Singapore.